The Available Low Molecular Weight Heparin Preparations Are Not the Same

Fareed J. , Walenga JM , Kumar A. , Rock A. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemost1985; 11:155.

Fareed J. , Hoppensteadt D. , Huan X. , Racanelli A. Comparative study on the in vitro and in vivo activities of seven low molecular weight heparins. Hemostasis1989;18(suppl 3):3.

Abildgaard U. , Sandset P. Lindahl A. Tissue factor pathway inhibitor . In: Poller L , ed. Recent advances in blood coagulation. Edinburgh, U.K.: Churchill Livingstone, 1993:105-24.

Broze GJ Tissue factor pathway inhibitor and the current concept of blood coagulation . Blood Coagul Fibrinol1995;6:S7.

Van Dedem G , Nielsen JI Determinations of the molecular mass of low molecular mass (LMM) heparin . Pharmeuropa1991;3: 202-18.

Fareed J. , Walenga JM , Lassen M. , Borris L. , Hoppensteadt DA Pharmacologic profile of a low molecular weight heparin (Enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effects . Acta Chir Scand1990;156(suppl 556):75.

Cade JF , Buchanan MR , Boneu B. , Ockelford P. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the preparation. Thromb Res1984;35:613.

Fareed J. , Kumar A. , Rock A. , Walenga JM , Davis P. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions. Semin Thromb Hemost1985 ;11:138.

Raake W. , Elling H. Rat jugular vein hemostasis-a new model for testing antithrombotic agents . Thromb Res1989;53:73-7.

Barrowcliffe TW Annotation: low molecular weight heparins . Bi-J Hematol1995;90:1.

Luldahl AK , Abilgaard U. , Larsen ML , Aamodt LM , Nordfang O. , Beck TC Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin-induced coagulation. Thromb Res1991;64:155.

Abildgaard U. Relative role of tissue factor pathway inhibitor and antithrombin in the control of thrombogenesis. Blood Coagul Fibrinol1995;6:545.

Broze GJ Jr.Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinol1995;6:S7.

Hoppensteadt DA , Jeske W. , Fareed J. , Bermes EW Jr.The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low molecular weight heparin. Blood Coagul Fibrinol1995 ;6:S57.

Bognacki J. , Hammelburger J. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coagul Fibrinol1995;6:S65.

Lindahl AK , Sandset PM , Abilcigaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinol1992;3:439.

Petersen CC , Bjorn SE , Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost1991 ;67:537.

Jeske W. , Hoppensteadt D. , Klausen R. , et al. Effect of repeated aprosulate and enoxaparin administration on TFPI antigen levels. Blood Coagul Fibrinol1995;6: 119.

Hoppensteadt D. , Walenga JM , Fasanella A. , Jeske W. , Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res1995;77:175.

Fareed J. Basic and applied pharmacology of low molecular weight heparins. Pharm Ther1995;16s-24s.

Fareed J. , Walenga JM , Pifarre R. Newer approaches to the pharmacologic management of acute myocardial infarction. CardiacSurg1992;6:101.

Fareed J. , Callas D. , Hoppensteadt D. , Jeske W. , Walenga JM Recent developments in antithrombotic agents. Invest Exp Opin Drugs1995;4:389-412.

Fareed J. , Walenga JM , Hoppensteadt DA , Racanelli A. , Coyne E. Chemical and biochemical heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin Thromb Hemost1989; 15:440.

Fareed J. , Callas D. , Hoppensteadt D. , Jeske W. , Walenga JM Recent developments in antithrombotic agents. Exp Opin Invest Drugs1995;4:389.

Fareed J. , Walenga JM , Pifarre R. Newer approaches to the pharmacologic management of acute myocardial infarction . Cardiac Surgery: State of the Art Reviews1992;6: 101.

Hirsh J. , Siragusa S. , Cosmi B. , Ginsberg JS Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost1995 ;74:360-363.

Hanke H. , Oberhoff M. , Hanke S. , et al. Inhibition of cellular proliferation after experimental balloon nogioplasty by low molecular weight heparin. Circulation1992;85:1548.

Schmid KM , Preisack M. , Voelken W. Sujatta M. Karsch KR First clinical experience with low molecular weight heparin LU 47311 (Reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty . Semin Thromb Hemost1993;19:155.

Kakkar VV Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE), Thromb Haemostas1995;74:368.

Fareed J. Hoppensteadt D , Walenga JM A perspective on low molecular weight heparins in the management of thrombosis. Haemostaseologie1993;13:S5.

Differentiation of beef and pig mucosal heparins by NMR spectroscopy [Letter]. Thromb Haemostast1995;74.1197-207.

Fareed J. , Hoppensteadt D. , lyer L. Impact of biotechnology in the diagnostic and therapeutic management of cardiovascular disorders. In: Longnecker JB , ed. Nutrition and biotechnology in heart disease and cancer. New York: Plenum Press, 1995:99-110.

Fareed J. , Callas D. , Hoppensteadt D. , Jeske W. , Walenga JM Recent developments in antithrombotic agents. Exp Opin Invest Drugs1995;4:389.

Agnelli G. , Iorlo A. , Renga C. , Boschetti E. , Nenci GG , Ofosu FA Prolonged antithrombin activity of low molecular weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation1995;92:2819-24.

Raskob GE Low molecular weight heparin for the prevention and treatment of venous thromboembolism . Curr Opin Pulmonary Med1996;2:305-10.

Fareed J. , Walenga JM , Hoppensteadt D. , Huan X. , Nonn R. Biochemical and pharmacologic inequivalence of low molecular weight heparins . Ann NY Acad Sci1989;556:333-53.

Fareed J. , Callas DD , Hoppensteadt D. , Jeske W. , Walenga JM Recent developments in antithrombotic agents. Exp Opin Invest Drugs1995;4:389-412.

Brieger D. , Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost1997;77:317-22.

Collignon F. , Frydman A. , Caplain H. , et al. Comparison of the pharmacokinetie profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin—administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism) . Thromb Haemost1995;73:630-40.

Eriksson BI , Söderberg K. , Widlund L. , Wandeli B. , Tengbom L. Risberg B. A comparative study of three low-molecular weight beparins (LMWH) and unfractionated heparin (UH) in healthy volunteers . Thromb Haemost1995;73:398-401.

Boneu B. Low molecular weight heparin therapy: is monitoring needed?Thromb Haemost1994;72:330-4.

Samama M. Contemporary laboratory monitoring of low molecular weight heparins . Thromb Haemost1995;15:119-23.

Hoppensteadt DA , Jeske W. , Fareed J. Laboratory monitoring of new anticoagulant and antithrombotic drugs. In: Pifarré R , ed. New anticoagulants for the cardiovascular patient. Philadelphia: Hanley & Belfus, 1997:521-38.

Hawkins DW Global economic perspective on the use of low molecular weight heparin . Clin Appl Thromb Hemost1996;2(suppl 1): S40-3.

Hull RD , Feldstein W. , Stein PD , Pineo GF Cost-effectiveness of pulmonary embolism diagnosis. Arch Intern Med1996; 156:68-78.

Hirsh J. , Raschke R. , Warkentin TE , Dalen JE , Deykin D. , Poller L. Chest1995;108(suppl 4):258S-75S.